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Can the Horse Be Put Back in the Barn?*Matthew T. Wheeler, MD, PHD, Euan A. Ashley, DPHILSEE PAGE 560H ypertrophic cardiomyopathy (HCM), aninherited disease of the heart muscle, isamong the most common Mendelian car-
diac diseases, occurring in 1 in 500 people (1).
Advances in genetics have facilitated identiﬁcation
of a subpopulation of patients with pathogenic vari-
ants in cardiac sarcomere genes. The earliest family
mapped by positional cloning had a disease-causing
mutation at position 403 of the b-myosin heavy chain
(MHC) protein (2). A knock-in mouse model of this
variant recapitulated aspects of human disease (3);
many other sarcomere genes have been implicated
subsequently (4). In clinics today, coding regions of
numerous cardiac sarcomere genes are routinely
sequenced, and, excluding those patients with
discrete upper septal thickening, clearly pathogenic
variants are identiﬁed in 30% to 50% of patients (5),
thus marking a subset of “sarcomeric” HCM.
Current therapy for HCM is primarily palliative.
Beta-blockers, nondihydropyridine calcium channel
blockers, and the class Ia antiarrhythmic agent dis-
opyramide are used for their negative inotropic and
chronotropic and positive lusitropic effects (6,7).
When these medications fail to alleviate symptoms,
more invasive options for obstructive patients are
recommended, such as surgical septal reduction or
alcohol septal ablation (8). In patients at sufﬁciently
high risk of sudden cardiac death, cardioverter-
deﬁbrillators are implanted.
Given this limited treatment armamentarium,
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Novel approaches based on promising preclinical data
showing prevention or regression of phenotype have
led to ongoing clinical trials of angiotensin receptor
blockade, statins, moderate-intensity exercise, and
N-acetylcysteine. These therapeutic approaches have
been joined in recent years by interest in gene
silencing (9–11) and targeting the late sodium current
(12) or the molecular motor itself (13). A critical
question for all these approaches is as follows: Can
treatment be given at any time, or is administration
necessary before disease is established? Essentially, is
the disease reversible? Or does the fact that HCM
tends to progress during the growth spurt of the
teenage years suggest an “irreversible” pathophysio-
logical state?In this context, the paper from Cannon et al. (14) in
this issue of the Journal is of particular interest.
These investigators created a new transgenic mouse
model of the MHC R403Q mutation and tied it to a
doxycycline-responsive element in a “gene-off” con-
ﬁguration. During placebo treatment, transgenic ani-
mals carrying 2 endogenous copies of the mouse
a-MHC, as well as transgenes expressing mutant
a-MHC under control of the doxycycline-responsive
element, experienced progressive hypertrophy as
well as dilation and reduction in ventricular function.
Normal, nontransgenic mice did not. The inves-
tigators studied the effect of giving doxycycline to
suppress the aMHC transgene at 3 time points: 20 to
40 weeks, 6 to 40 weeks, and 0 to 6 weeks (from the
time of conception, which is possible because doxy-
cycline crosses the placenta). These investigators
found that disease manifestations were suppressed
only in the group treated from conception.
This study is notable because it provides one of the
ﬁrst insights into the timing of murine disease onset. A
lack of reversibility of human disease would have
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571important implications for disease-modifying drugs
currently in development. There may also be trans-
lational relevance for proactive family screening; for
early identiﬁcation, screening with genetic testing,
echocardiography, and electrocardiography would be
required more consistently at a younger age than
guidelines currently endorse.
Given these far-reaching implications, can we as-
sume that such an effect extends to humans? Although
the study investigators showed the effects of treat-
ment on transgene suppression and normalization of
transgene protein at one time point, we cannot tell
from the presented data whether there is treatment
escape with age. In other words, was the doxycycline
dose given later in adulthood adequate to suppress
transgene expression at that time? We also do not
know whether mutant transgene protein persisted in
the myocardium of adult mice treated with doxycy-
cline starting at 6 or 20 weeks. The investigators noted
a variable effect of the transactivator system on left
ventricular hypertrophy in mice, but these mice did
not serve as comparator controls.
In assessing translational relevance, we must
remember that mice and humans differ greatly.
Notably, none of the HCM mouse models displays
asymmetric hypertrophy or a left ventricular outﬂow
tract gradient, 2 pathognomonic features of the dis-
ease. Further, mice express a different dominant MHC
isoform (a) than do humans (b); these 2 molecules
diverge both anatomically and functionally. Although
fetal isoforms are more similar to human, a funda-
mental “switch” happens in the mouse but not human
postnatal period at exactly the time these data suggest
may be critical to the trigger for apparently irreversible
disease.
What about reversibility itself? In fact, we are ac-
customed to expect reversibility given our experi-
ences with reverse remodeling in patients with treated
valve disease, treated hypertension, or chronic kidney
disease treated with renal transplantation. Decades of
work show that inhibiting the renin-angiotensin-
aldosterone system reverses cardiac ﬁbrosis. Previ-
ous investigators demonstrated an ability to preventor reverse ﬁbrosis in HCM (15–17). In a bigenic mouse
model with expression of the R92Q variant of troponin
T type 2 (18), for example, removal of stimulation with
mifepristone during adulthood led to ﬁbrosis regres-
sion and a change in pathological markers. Impor-
tantly, drug treatment was required for expression,
not suppression, of transgene activity. The same
group examined 2-year-old rabbits that, like humans,
express predominantly the cardiac b-myosin. After 12
months of therapy with N-acetylcysteine, these in-
vestigators observed reversal of established cardiac
hypertrophy and interstitial ﬁbrosis (17).
Currently, it is unclear how to resolve these
apparently disparate observations. Maybe, for certain
mutations, an abnormal transcript or protein leads to
a state shift in cardiomyocytes or ﬁbroblasts from
normal to pathological and that suppressing gene
transcription, even to the point of replacing presum-
ably all the mutant protein, may not be sufﬁcient to
push the cellular state back toward normal. For this to
occur, a signal would need to trigger a response that
was subsequently self-sustaining and quite different
in its transduction from the reversible remodeling
described earlier.
Candidates for such processes could include
calmodulin kinase II or chromatin remodeling. Such
a construct could explain why treatment with
N-acetylcysteine or exercise may lead to reversal,
whereas allele silencing or transgene suppression
alone did not in these studies. Perhaps adjunctive
therapies focused on pushing downstream gene
expression programs or protein signaling networks
back to a steady-state normal may be required for
treatment of disease in adults.
The current work lends important insight to our
understanding of the pathophysiological basis of this
disease, and it is especially timely as we move with
cautious optimism toward targeted therapies.
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